Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
04/2014
04/01/2014US8685398 Chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
04/01/2014US8685397 Combination therapy for the treatment of ocular neovascular disorders
04/01/2014US8685396 Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin
04/01/2014US8685395 Methods of antagonizing signal transduction in dorsal root ganglion cells
04/01/2014US8685394 Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
04/01/2014US8685393 Methods and compositions for the treatment and diagnosis of systemic anthrax infection
04/01/2014US8685384 Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex
04/01/2014CA2696630C Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
04/01/2014CA2649426C Recombinant attenuated clostridium organisms and vaccine
04/01/2014CA2605165C Coccidial vaccine and methods of making and using same
04/01/2014CA2596730C Adjuvanting material comprising pam2cys or pam3cys covalently linked to a metal chelating group
04/01/2014CA2589521C Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers
04/01/2014CA2569590C Drug having regulatory cell ligand contained in liposome
04/01/2014CA2556436C Process for preparing anit-a.beta. antibody
04/01/2014CA2544692C Anti-glypican 3 antibody
04/01/2014CA2544368C Methods of therapy for b cell-related cancers
04/01/2014CA2515444C Immunoglobulin formulation and method of preparation thereof
04/01/2014CA2504920C Ligand for g-protein coupled receptor fprl2 and uses thereof
04/01/2014CA2498523C Human cd3-specific antibody with immunosuppressive properties
04/01/2014CA2493928C Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer
04/01/2014CA2433561C Compositions including gram negative siderophore receptor proteins and methods of use
04/01/2014CA2423122C Closure of bacterial ghosts
04/01/2014CA2420062C Erbb4 antagonists
04/01/2014CA2413354C Neurotoxic a.beta. oligomers in alzheimer's disease
03/2014
03/27/2014WO2014047625A1 Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
03/27/2014WO2014047588A1 Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
03/27/2014WO2014047533A1 Improved vaccine compositions and methods of use
03/27/2014WO2014047426A1 Methods of treating hematological malignancies with notch1 antibodies
03/27/2014WO2014047357A1 Modified fc polypeptides, fc conjugates, and methods of use thereof
03/27/2014WO2014047350A1 Oncolytic virus encoding pd-1 binding agents and uses of the same
03/27/2014WO2014047286A1 Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
03/27/2014WO2014047261A1 Viruses associated with immunodeficiency and enteropathy and methods using same
03/27/2014WO2014047251A1 Methods of treating pulmonary fibrosis
03/27/2014WO2014047231A1 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
03/27/2014WO2014046994A1 Compositions and methods for antigen targeting to cd180
03/27/2014WO2014046624A1 A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway
03/27/2014WO2014045621A1 Pneumococcal vaccine containing pneumococcal surface protein a
03/27/2014WO2014045266A1 Treatment of type 2 diabetes and related conditions
03/27/2014WO2014045226A1 Clostridium difficile polypeptides as vaccine
03/27/2014WO2014045213A1 Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
03/27/2014WO2014045084A1 Fusion proteins with representation of different allergens: vaccine proposal for mite allergies
03/27/2014WO2014045081A1 Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
03/27/2014WO2014045023A1 Treatment of post-traumatic stress disorder with isolated mycobacterium
03/27/2014WO2014045022A2 Agents and methods
03/27/2014WO2014044768A1 Treatment for rheumatoid arthritis
03/27/2014WO2014044728A1 Outer membrane vesicles
03/27/2014WO2014044690A1 Improved vaccines
03/27/2014WO2014043838A1 Method of preparing broad spectrum vaccine for preventing avian colibacillosis
03/27/2014WO2014020291A3 Mutant strains of neospora and uses thereof
03/27/2014WO2014018572A3 Immunoglobulin constructs comprising selective pairing of the light and heavy chains
03/27/2014WO2014012085A3 Bispecific asymmetric heterodimers comprising anti-cd3 constructs
03/27/2014WO2013188673A3 Reassortant btv and ahsv vaccines
03/27/2014WO2013181618A3 Methods to treat alzheimer's disease using apoe inhibitors
03/27/2014WO2013177593A3 Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
03/27/2014WO2013165894A3 St2l antagonists and methods of use
03/27/2014WO2013096335A8 ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
03/27/2014WO2012012271A3 Novel glycosylated polypeptides
03/27/2014US20140088502 Multi-Needle Injection Apparatus and System for Delivering Pharmacological Agents to Biological Tissue
03/27/2014US20140088296 Il-18 binding proteins
03/27/2014US20140087422 Nucleic acids related to fusion proteins
03/27/2014US20140087399 Assay method for peptide specific t-cells
03/27/2014US20140087384 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues
03/27/2014US20140086989 Protein Matrix Vaccine Compositions Including Polycations
03/27/2014US20140086988 Stabilized Protein Crystals, Formulations Containing Them and Methods of Making Them
03/27/2014US20140086974 Biodegradable drug delivery systems for the sustained release of proteins
03/27/2014US20140086957 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
03/27/2014US20140086956 Adjuvant for the preparation of vaccine compositions intended for the prevention of coccidiosis
03/27/2014US20140086955 Attenuated Live Vaccines for Aquatic Animals
03/27/2014US20140086952 Vaccine Adjuvants from Self-Assembling Peptides
03/27/2014US20140086950 Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
03/27/2014US20140086948 Tuberculosis rv2386c protein, compositions and uses thereof
03/27/2014US20140086947 Vaccines for hsv-2
03/27/2014US20140086944 DNA VACCINE CONTAINING SPECIFIC EPITOPE OF APOLIPOPROTEIN (a)
03/27/2014US20140086943 Novel and powerful mhc-class ii peptides derived from survivin
03/27/2014US20140086940 Herceptin® adjuvant therapy
03/27/2014US20140086939 Compositions and methods for detecting and treating cancer
03/27/2014US20140086937 Immunological control of beta-amyloid levels in vivo
03/27/2014US20140086935 Human TIMP-1 Antibodies
03/27/2014US20140086933 Treatment of Diabetes
03/27/2014US20140086932 Method for enhancing specific immunotherapies in cancer treatment
03/27/2014US20140086931 Formulation of human antibodies for treating tnf-alpha associated disorders
03/27/2014US20140086930 Formulation of human antibodies for treating tnf-alpha associated disorders
03/27/2014US20140086929 Formulation of human antibodies for treating tnf-alpha associated disorders
03/27/2014US20140086926 Method of combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
03/27/2014US20140086925 Fgfr1 antibodies and treatment of cancer
03/27/2014US20140086924 Compounds that inhibit hsp90 protein-protein interactions with iap proteins
03/27/2014US20140086921 Methods of Treating a Tauopathy
03/27/2014US20140086917 COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
03/27/2014US20140086915 Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
03/27/2014US20140086914 TREATMENT METHODS USING c-MET ANTIBODIES
03/27/2014US20140086908 Anti-alpha-v integrin antibody for the treatment of prostate cancer
03/27/2014US20140086907 Multimodal trail molecules and uses in cellular therapies
03/27/2014US20140086905 Immunological compositions as cancer therapeutics
03/27/2014US20140086903 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
03/27/2014US20140086901 Inhibition of Post-Radiation Tumor Growth
03/27/2014US20140086888 Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
03/27/2014US20140086872 Methods of Treating a Subject for a Condition
03/27/2014US20140086869 Methods and compositions for treating tumors using myeloid derived suppressor cells
03/27/2014US20140086832 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
03/27/2014US20140086831 Single Wall Nanotube Constructs and Uses Thereof
1 ... 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 ... 1823